SUMMIT Trial: Tirzepatide for Heart Failure, Preserved Ejection Fraction and Obesity

he SUMMIT trial compared the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results from the trial concluded that treatment of obesity reduces major heart failure events in addition to improving health status and exercise tolerance.  In this interview, Drs. Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL